HMG-CoA减小酶抑制剂和骨折的风险
C R Meier1, R G Schlienger, M E Kraenzlin
1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. Christoph.Meier@unibas.ch
JAMA
|June 24, 2000
概括
降胆固醇药的一种类型的他类药物,在50岁以上的人群中显著降低骨折风险. 这与纤维酸和其他降脂药物形成鲜明对比,这些药物对骨折预防没有显著影响.
科学领域:
- 药理学 药理学是指药理学的学科.
- 骨的新陈代谢 骨的新陈代谢
- 流行病学 流行病学
背景情况:
- 动物研究表明,HMG-CoA减少酶抑制剂 (他类药物) 增强骨形成,体积和密度.
- 关于他类药物使用与骨折风险之间的联系的人类数据有限.
研究的目的:
- 调查他类药物,纤维酸盐或其他降脂药物是否与骨折风险降低有关.
- 评估降脂药物对骨健康结果的影响.
主要方法:
- 基于人口的,嵌套的病例对照研究,使用英国通用实践研究数据库 (GPRD).
- 分析包括超过91,000名50岁以上的个人,将骨折病例 (n=3940) 与对照病例 (n=23,379) 进行比较.
- 根据BMI,吸烟,医生访问,皮质类固醇和雌激素使用情况进行调整.
主要成果:
- 当前使用他类药物显著与骨折风险降低有关 (调整后OR,0.55;95%CI,0.44-0.69).
- 纤维酸和其他降脂药物与骨折风险降低没有显著关联.
- 纤维化物和其他降脂药物的调整后几率比分分别为0.87 (95% CI,0.70-1.08) 和0.76 (95% CI,0.41-1.39).
结论:
- 目前的他类药物暴露似乎与50岁及以上的个体骨折风险较低有关.
- 这些发现表明,他类药物对骨健康有潜在的公共卫生益处.
- 建议通过前性试验进一步确认.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:25Pharmacokinetics: Drug–Drug Interactions
816
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
816
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:30Drug toxicity: Drug–Drug Interaction
437
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747